ImmunoPrecise Antibodies (IPA) has released an update.
ImmunoPrecise Antibodies Ltd. has announced that its subsidiary BioStrand received the 2024 Impact Award for its innovative LENSai™ technology, marking a significant advancement in biotherapeutic research. The award, which recognizes exceptional contributions out of over 1,000 client projects, highlights BioStrand’s prominent role in setting new standards for the industry. This achievement showcases the company’s dedication to innovation and its influence as a benchmark for others in the field.
For further insights into IPA stock, check out TipRanks’ Stock Analysis page.
